Jupiter Neurosciences Lands Potential $100 Million Psychedelic Drug Deal as PharmAla Licenses ALA-002
Momentum continues to build across the emerging psychedelic medicine sector as PharmAla Biotech (OTCQB:MDXXF) announced a definitive licensing agreement granting Jupiter Neurosciences (NASDAQ:JUNS) exclusive rights to develop, manufacture, and commercialize ALA-002 in the United States. The agreement, valued at up to approximately US$100 million in potential consideration, reflects the growing interest in next-generation neuropsychiatric therapies and strategic partnerships designed to advance promising clinical assets while managing development risk.